Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

M-Vax shown to induce T-cell-mediated immune reactions in metastatic melanoma study

April 11, 2000

Dendreon describes preparation and use of apoptosis-inducing HLA-DR-specific MAbs

April 10, 2000

Health Canada approves Rituxan for treatment of NHL

April 7, 2000

Oncolytics Biotech's pilot canine study of Reolysin shows measurable tumor response

April 4, 2000

Avax begins phase II study of M-Vax in stage IV metastatic melanoma

April 3, 2000

AltaRex presents clinical plan for OvaRex at BIO 2000 annual meeting

March 30, 2000

SRL-172 associated with significantly improved survival in SCLC patients

March 28, 2000

Phase I clinical study to begin with Reolysin as cancer treatment

March 27, 2000

FDA grants orphan drug status to Zadaxin for treatment of liver cancer

March 24, 2000

Phase I study of AltaRex's BrevaRex MAb completed

March 22, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...